Mito-Tempol and Dexrazoxane Exhibit Cardioprotective and Chemotherapeutic Effects through Specific Protein Oxidation and Autophagy in a Syngeneic Breast Tumor Preclinical Model

• Jennifer S. Dickey ,

  Contributed equally to this work with: Jennifer S. Dickey, Yanira Gonzalez

  Current address: Office of In Vitro Diagnostics, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, Maryland, United States of America

  Affiliation Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America

  ⨯
• Yanira Gonzalez ,

  Contributed equally to this work with: Jennifer S. Dickey, Yanira Gonzalez

  Affiliation Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America

  ⨯
• Baikuntha Aryal,

  Affiliation Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America

  ⨯
• Steven Mog,

  Affiliation Center for Food Safety and Applied Nutrition, Food and Drug Administration, College Park, Maryland, United States of America

  ⨯
• Asako J. Nakamura,

  Current address: Department of Biological Sciences, Ibaraki University, Ibaraki, Japan

  Affiliation Laboratory of Molecular Pharmacology, National Cancer Institute, Bethesda, Maryland, United States of America

  ⨯
• Christophe E. Redon,

  Affiliation Laboratory of Molecular Pharmacology, National Cancer Institute, Bethesda, Maryland, United States of America

  ⨯
• Ulrich Baxa,

  Affiliation Electron Microscopy Laboratory, Advanced Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America

  ⨯
• Elliot Rosen,

  Affiliation Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America

  ⨯
• Gang Cheng,

  Affiliation Department of Biophysics and Free Radical Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America

  ⨯
• Jacek Zielonka,

  Affiliation Department of Biophysics and Free Radical Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America

  ⨯
• Palak Parekh,

  Affiliation Laboratory of Molecular Pharmacology, National Cancer Institute, Bethesda, Maryland, United States of America

  ⨯
• Karen P. Mason,

  Affiliation Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America

  ⨯
• Joy Joseph,

  Affiliation Department of Biophysics and Free Radical Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America

  ⨯
• Balaraman Kalyanaraman,

  Affiliation Department of Biophysics and Free Radical Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America

  ⨯
• William Bonner,

  Affiliation Laboratory of Molecular Pharmacology, National Cancer Institute, Bethesda, Maryland, United States of America

  ⨯
• Eugene Herman,

  Affiliation Division of Drug Safety Research, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯
• Emily Shacter,

  Affiliation Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America

  ⨯
•  [ ... ],
• V. Ashutosh Rao

  * E-mail: ashutosh.rao@fda.hhs.gov

  Affiliation Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America

  ⨯
• [ view all ]
• [ view less ]